Merck

BMS chases Merck/Seagen with first-line bladder cancer filing
BMS chases Merck/Seagen with first-line bladder cancer filing
Pharmaphorum
Bristol Myers Squibb
Opdivo
bladder cancer
urothelial cancer
Merck
Seagen
Flag link:
FDA starts review of Padcev/Keytruda for bladder cancer
FDA starts review of Padcev/Keytruda for bladder cancer
Pharmaphorum
Merck
Astellas
Seagen
Padcev
bladder cancer
FDA
priority review
Flag link:
After watching Merck's chronic cough drama, GSK knew exactly what not to do with Bellus asset
After watching Merck's chronic cough drama, GSK knew exactly what not to do with Bellus asset
Fierce Biotech
Merck
GSK
chronic cough
Bellus Health
gefapixant
Camlipixant
Flag link:
Merck turns to Acclinate to increase African American participation in cancer trials
Merck turns to Acclinate to increase African American participation in cancer trials
Fierce Biotech
Merck
clinical trials
clinical trial diversity
Acclinate
cancer
digital health
Flag link:
Merck strides onto Pfizer’s turf, posting pivotal vaccine data and heading to regulators
Merck strides onto Pfizer’s turf, posting pivotal vaccine data and heading to regulators
Fierce Pharma
Merck
Pfizer
vaccines
clinical trials
pneumococcal disease
V116
Prevnar 20
Flag link:
Merck Drops Up to $610M on Neuro Disease-Focused Caraway Therapeutics
Merck Drops Up to $610M on Neuro Disease-Focused Caraway Therapeutics
BioSpace
Merck
M&A
neurodegenerative disease
Caraway Therapeutics
Flag link:
5 Cancer Vaccines to Watch in 2024
5 Cancer Vaccines to Watch in 2024
BioSpace
Merck
Moderna Therapeutics
melanoma
BioNTech
pancreatic cancer
OSE Immunotherapeutics
Transgene
non-small cell lung cancer
Nykode Therapeutics
cervical cancer
Flag link:
FDA panel flags insufficient data for Merck's chronic cough drug
FDA panel flags insufficient data for Merck's chronic cough drug
Reuters
Merck
FDA
chronic cough
gefapixant
Flag link:
Merck Expands Keytruda’s Label as a First-Line Option for Gastric Cancer
Merck Expands Keytruda’s Label as a First-Line Option for Gastric Cancer
BioSpace
Merck
Keytruda
gastric cancer
Flag link:
FDA skeptical of Merck’s gefapixant, even after cough recount
FDA skeptical of Merck’s gefapixant, even after cough recount
Fierce Biotech
Merck
chronic cough
gefapixant
Flag link:
Merck-backed VectorY Therapeutics raises $138M series A to push forward ALS program
Merck-backed VectorY Therapeutics raises $138M series A to push forward ALS program
Fierce Biotech
VectorY Therapeutics
funding
ALS
Merck
Flag link:
Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?
Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?
Motley Fool
Merck
Bristol Myers Squibb
antibody-drug conjugate
Flag link:
Merck's Keytruda nabs FDA nod in biliary tract cancer, catching up with AstraZeneca's Imfinzi
Merck's Keytruda nabs FDA nod in biliary tract cancer, catching up with AstraZeneca's Imfinzi
Fierce Pharma
Merck
AstraZeneca
biliary tract cancer
Keytruda
Imfinzi
Flag link:
Daiichi-Sankyo ups revenue forecast thanks to massive Merck deal
Daiichi-Sankyo ups revenue forecast thanks to massive Merck deal
Fierce Biotech
Daiichi Sankyo
Merck
antibody-drug conjugate
Flag link:
‘We knew it was there’: AbbVie CEO says company favored internal work over potential Daiichi deal
‘We knew it was there’: AbbVie CEO says company favored internal work over potential Daiichi deal
Fierce Biotech
AbbVie
Daiichi Sankyo
Merck
antibody-drug conjugate
Flag link:
Tricks and Treats as Biopharma’s Q3 Earnings Season Gets Underway
Tricks and Treats as Biopharma’s Q3 Earnings Season Gets Underway
BioSpace
earnings
Bristol Myers Squibb
Takeda
Novartis
Sanofi
Merck
Flag link:
Merck quarterly profit tops expectations on COVID pill surprise
Merck quarterly profit tops expectations on COVID pill surprise
Yahoo/Reuters
Merck
earnings
COVID-19
Flag link:
Merck terminates Phase II trials for Alzheimer’s drug due to liver toxicity
Merck terminates Phase II trials for Alzheimer’s drug due to liver toxicity
Clinical Trials Arena
Merck
clinical trials
MK-1942
liver toxicity
Alzheimer's disease
Flag link:
Merck discontinues some cancer drug development with China's Sichuan Kelun
Merck discontinues some cancer drug development with China's Sichuan Kelun
Reuters
Merck
Sichuan Kelun Pharmaceutical
cancer
oncology
Flag link:
Merck, BMS Score Separate Late-Stage Victories in Bladder Cancer at ESMO
Merck, BMS Score Separate Late-Stage Victories in Bladder Cancer at ESMO
BioSpace
ESMO
Merck
Bristol Myers Squibb
bladder cancer
PD-1 inhibitors
Keytruda
Padcev
Opdivo
Flag link:

Pages